Albireo to Present at the William Blair Biotech Focus Conference 2022

Rhea-AI Summary

Albireo Pharma (Nasdaq: ALBO) will participate in the William Blair Biotech Focus Conference on July 12-13, 2022. CEO Ron Cooper will engage in a fireside chat, while CFO Simon Harford will also hold meetings during the event. The fireside chat will be broadcasted on the company’s website and will be available for 30 days post-event. Albireo focuses on developing novel bile acid modulators to treat rare pediatric and adult liver diseases, with its leading product, Bylvay, recently approved by the U.S. FDA for treating pruritus in progressive familial intrahepatic cholestasis (PFIC).

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022. Ron Cooper, President and Chief Executive Officer, will take part in a fireside chat during the conference. Ron and Simon Harford, Chief Financial Officer, will also host meetings during the conference.

The fireside chat will be accessible on the Albireo website under the Events & Presentations page at https://ir.albireopharma.com/events-presentations, and will be archived and available for 30 days following the event.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay has been approved for the treatment of PFIC with pricing listing in Germany and guidance from the National Institute for Health and Care Excellence (NICE) recommending Bylvay for use in the National Health Service in England, Wales and Northern Ireland. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com 
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

What is Albireo Pharma's participation in the William Blair Biotech Focus Conference?

Albireo Pharma will participate in the William Blair Biotech Focus Conference on July 12-13, 2022, with CEO Ron Cooper hosting a fireside chat.

Where can I watch the Albireo Pharma fireside chat?

The fireside chat can be accessed on Albireo's website under the Events & Presentations page and will be available for 30 days after the event.

What is the significance of Albireo's product Bylvay?

Bylvay is significant as it is the first FDA-approved treatment for pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).

What other developments is Albireo Pharma working on?

Albireo is also advancing Bylvay for other rare liver diseases and has completed Phase 1 trials for A3907 for adult cholestatic liver disease.

When was Bylvay approved by the FDA?

Bylvay was approved by the U.S. FDA for the treatment of pruritus in PFIC, marking a milestone in rare liver disease treatment.